


Patent Claims

1. Compounds of the general formula I



in which

A is an acetyl or a 3-(4-fluorophenyl)propionyl group,


X_{xx}^1 is D-Nal(1) or D-Nal(2),

X_{xx}^2 - X_{xx}^3 is D-Cpa-D-Pal(3) or a single bond,

X_{xx}^4 is Ser,

X_{xx}^5 is N-Me-Tyr,

X_{xx}^6 is D-Cit, D-Hci or a D-amino acid group of the general formula (II)




(II)

in which n is the number 3 or 4, where R¹ is a group having the general formula III



where p is an integer from 1 to 4, R² is hydrogen or an alkyl group and R³ is an unsubstituted or substituted aryl group or heteroaryl group, or R¹ is a 3-amino-1,2,4-triazole-5-carbonyl group or R¹ is a ring of the general formula (IV)



in which q is the number 1 or 2, R⁴ is a hydrogen atom or an alkyl group, R⁵ is a hydrogen atom or an alkyl group and X is an oxygen or sulphur atom,
 5 Xxx⁷ is Leu or Nle,
 Xxx⁸ is Arg or Lys(iPr),
 Xxx⁹ is Pro and
 Xxx¹⁰ is Ala, D-Ala or Sar,
 10 and their salts with pharmaceutically acceptable acids.

2. Compounds according to Claim 1, in which the salt is an acetate, trifluoroacetate or embonate.
- 15 3. Compounds according to Claim 1 or 2, in which Xxx⁶ is D-[ε-N'-(imidazolidin-2-on-4-yl)formyl]-Lys, D-(3-amino-1,2,4-triazole-3-carbonyl)-Lys, abbreviated D-Lys(Atz) or D-[ε-N'-4-(4-amidino-phenyl)amino-1,4-dioxobutyl]-Lys, abbreviated
 20 D-Lys(B).
4. Compound according to Claim 1 having the formula:
 Ac-D-Nal(2)¹-D-Cpa²-D-Pal(3)³-Ser⁴-N-Me-Tyr⁵-D-Hci⁶-
 25 Nle⁷-Arg⁸-Pro⁹-D-Ala¹⁰-NH₂.
5. Compound according to Claim 1 having the formula:
 Ac-D-Nal(2)¹-D-Cpa²-D-Pal(3)³-Ser⁴-N-Me-Tyr⁵-D-Lys(Atz)⁶-Leu⁷-Arg⁸-Pro⁹-D-Ala¹⁰-NH₂.
- 30 6. Compound according to Claim 1 having the formula:
 Ac-D-Nal(2)¹-D-Cpa²-D-Pal(3)³-Ser⁴-N-Me-Tyr⁵-D-Lys(B)⁶-Leu⁷-Lys(iPr)⁸-Pro⁹-D-Ala¹⁰-NH₂.

7. Compound according to Claim 1 having the formula:
Ac-D-Nal(2)¹-D-Cpa²-D-Pal(3)³-Ser⁴-N-Me-Tyr⁵-D-
Lys(B)⁶-Leu⁷-Arg⁸-Pro⁹-D-Ala¹⁰-NH₂.
- 5 8. Compound according to Claim 1 having the formula:
Ac-D-Nal(2)¹-D-Cpa²-D-Pal(3)³-Ser⁴-N-Me-Tyr⁵-D-Hci⁶-
Nle⁷-Lys(iPr)⁸-Pro⁹-D-Ala¹⁰-NH₂.
- 10 9. Compound according to Claim 1 having the formula:
Ac-D-Nal(2)¹-D-Cpa²-D-Pal(3)³-Ser⁴-N-Me-Tyr⁵-D-Hci⁶-
Nle⁷-Lys(iPr)⁸-Pro⁹-Sar¹⁰-NH₂.
- 15 10. Compound according to Claim 1 having the formula:
Ac-D-Nal(2)¹-D-Cpa²-D-Pal(3)³-Ser⁴-N-Me-Tyr⁵-D-Hci⁶-
Nle⁷-Arg⁸-Pro⁹-Sar¹⁰-NH₂.
- 20 11. Compound according to Claim 1 having the formula:
3-(4-fluorophenyl)propionyl-D-Nal(1)¹-Ser⁴-N-Me-
Tyr⁵-D-Lys(Atz)⁶-Leu⁷-Arg⁸-Pro⁹-D-Ala¹⁰-NH₂.
- 25 12. Compound according to Claim 1 having the formula:
Ac-D-Nal(2)¹-D-Cpa²-D-Pal(3)³-Ser⁴-N-Me-Tyr⁵-D-
Lys(B)⁶-Nle⁷-Arg⁸-Pro⁹-Sar¹⁰-NH₂.
- 30 13. Compound according to Claim 1 having the formula:
Ac-D-Nal(2)¹-D-Cpa²-D-Pal(3)³-Ser⁴-N-Me-Tyr⁵-D-
Lys(B)⁶-Nle⁷-Arg⁸-Pro⁹-D-Ala¹⁰-NH₂.
- 35 14. Compound according to Claim 1 having the formula:
Ac-D-Nal(2)¹-D-Cpa²-D-Pal(3)³-Ser⁴-N-Me-Tyr⁵-D-
Lys(B)⁶-Nle⁷-Lys(iPr)⁸-Pro⁹-Sar¹⁰-NH₂.
15. Pharmaceutical composition comprising a compound
according to one of Claims 1 to 14.
16. Process for the preparation of compounds of the
general formula I according to Claim 1, in which

5 fragments from units Xxx^m provided with suitable
protective groups, in which m is an integer from 1
to 10 and Xxx^1 is acetylated, are synthesized on a
solid phase or in solution according to customary
processes, then the fragments are linked to a
solid phase by segment coupling and after
conclusion of the coupling the compounds of the
general formula I are removed from the solid phase
using customary processes with amidation on the
10 unit Xxx^{10} .

17. Use of the substances according to Claims 1 to 14
for producing medicaments for the treatment of
hormone-dependent tumours, in particular prostate
15 carcinoma or breast cancer, and also for non-
malignant indications whose treatment necessitates
LH-RH hormone suppression.

18. Process for producing medicaments, in which
20 compounds according to Claims 1 to 14 are mixed
with the customary vehicles and excipients and
formulated as medicaments.